Journal article icon

Journal article

Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.

Abstract:

A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. After 18 months of treatment, he developed kidney injury and the treatment was discontinued. At 9 months and before the development of kidney injury, LY2181308 concentrations were 8- to 10-fold higher relative to median predicted values, but within the targeted exposure considered to be safe. However, at 17 months, 28 days after sto...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1053/j.ajkd.2010.09.024

Authors


Herrington, WG More by this author
Talbot, DC More by this author
Brandt, JT More by this author
Callies, S More by this author
Expand authors...
Journal:
American journal of kidney diseases : the official journal of the National Kidney Foundation
Volume:
57
Issue:
2
Pages:
300-303
Publication date:
2011-02-05
DOI:
EISSN:
1523-6838
ISSN:
0272-6386
URN:
uuid:1440b40a-cac3-4fd8-822a-adfc7a5ff3de
Source identifiers:
179122
Local pid:
pubs:179122

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP